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Treatment Sequencing Survival Model for patients with Multiple Myeloma ineligible for stem cell transplantation (SCT) Introduction
Multiple myeloma (MM) is a cancer of plasma cells. Symptoms include debilitating pain caused by bone damage. Multiple myeloma is responsible for 1% of all diagnosed cancers and constitutes 10% of all haematological malignancies. 1, 2 For younger patients (≤65 years), the preferred treatment option is high-dose chemotherapy followed by stem cell transplantation (SCT). [3] [4] [5] [6] Due to poor condition however, older patients (≥65 years) and a group of frail younger patients are ineligible for SCT. [3] [4] [5] [6] Treatment of MM is characterized by the consecutive application of several chemotherapies. MM is still incurable, so the main aim of the consecutive treatment lines (sequences) is to increase overall survival (OS). Median survival after diagnosis ranges from 36 to 60 months in SCT ineligible patients. [7] [8] [9] In clinical practice, a short-term marker for treatment success, and therefore aim of clinicians, is to reach complete response (CR) 10 , as CR is a predictor for OS in MM. [11] [12] [13] In the first line treatment of SCT ineligible patients, thalidomide (T) [14] [15] [16] [17] [18] [19] , bortezomib (V) [20] [21] [22] and lenalidomide (R) 23 are often combined with melphalan/prednisone (MP). In relapsed patients, these agents are typically combined with dexamethasone (D), but can also be administered as monotherapy. As a consequence, many treatment options, and therefore many treatment sequences, are available to physicians and patients over the course of the disease.
Randomized controlled trials (RCTs) are the gold standard to prove whether a treatment is superior over another. By definition, however, RCTs do not investigate the efficacy of treatment sequences and therefore evidence on the efficacy of treatment sequences is not available from RCTs. Nevertheless, the introduction of thalidomide, bortezomib, and lenalidomide over the past 7-15 years has improved survival and with an increasing number of therapies available there is a need to focus on the question of optimal sequence of treatments, as in current clinical practice doctors can choose among many treatment sequences. This sequencing question will probably become even more important in the near future, with new myeloma treatments entering the scene.
It is unrealistic to assume that finding the optimal treatment sequence in MM can be addressed in an RCT, as a wide array of treatment arms, thousands of patients and many years of follow-up would be required. Also, the result would probably be outdated by the time the results become known. Therefore, an alternative methodology is needed that allows for early evaluations of the clinical and economic benefits of different treatments in MM, taking their position in the treatment sequence into account. Hence, the objective of this study was to compare overall survival in patients receiving different treatment sequences, rather than focussing on individual treatment lines, with the help of a modelling framework.
Methods

Model outline
To estimate the median and mean OS of different sequences in MM, a Markov model 24 was developed with a lifetime horizon, considering four lines of treatment. In essence, a Markov model simulates the lifespan of patients in a hypothetical cohort dividing that into equal periods (cycles). A cycle length of one month was chosen for the model as this is the shortest interval at which the patients' response to therapy is typically measured in clinical practice. The model included the following health states: CR, partial response (PR), no response (NR) in first, second and third line treatment, and death ( Figure 1 ). Response categories were chosen for the health states because in clinical practice CR is an important marker for treatment success 10 in terms of OS. [11] [12] [13] At the start of the model patients are distributed over the response categories in first line based on the treatment they receive in first line. In each following monthly cycle, the members of the imaginary cohort progress through the model, i.e. they may remain in the current response state, switch treatment, or die. In the model, response rates (specific to the treatment itself and the line of treatment) are combined with the probability of switching treatment (specific to response category and line of treatment) and the mortality probability (specific to response and line of treatment). Patients who switch treatment are then redistributed over CR, PR and NR health states in second line, where they again may remain on treatment, switch treatment or die. This calculation process is repeated until the cohort of patients enters the "later lines of treatment" state where they remain until they die.
No direct evidence is available comparing CR, PR and NR for all first line treatments considered in this model, nor for treatments considered in the relapsed health states. Hence, the probabilities of response (CR, PR and NR) for patients receiving first, second and third line treatments were derived from a systematic literature review (SLR) and were combined in a network meta-analyses (NMA) to allow for an indirect comparison of the relevant treatments. The methodology used for the NMA is explained in the methods section whereas results of the NMA are presented in the results section. The way the transition probabilities for dying and switching to the next line of treatment are derived and the corresponding assumptions applied are presented later in the methods section. The actual transition probabilities are presented in the results section.
Systematic literature review (SLR) and data-extraction
To collect data on response (CR, PR and NR), time to progression (TTP, which was not used in the base case model), TTNT and OS, a SLR was conducted. The SLR focussed on the following treatments: T, R, V, D, MP, or combinations of these in first and later lines of MM treatment. 
Data Synthesis: estimating the inputs of the model
Estimating distribution of response according to type and line of treatment
Response data for the relevant treatments over the first three lines of treatment of the model were needed as input to fill the model. No response data for fourth line of treatment was needed as it was assumed that patients remain there until they die. The response data for the first three lines of treatment were extracted from the intention-to-treat (ITT) populations in the trials, first according to criteria from the European Group for Blood and Marrow Transplantation (EBMT) 25 , or, if EBMT was not available, from the International Myeloma Working Group (IMWG) 26 .
As CR, PR and NR were the most reported response types, other less often used or newer response types had to be pooled with one of these three response categories in order to be able to use as much of the retrieved data as possible for the modelling exercise. So, for this model: The number of patients per trial with CR, PR and NR retrieved from the RCTs were included in the NMA. In NMAs, binary outcomes are generally considered in a logistic framework with the odds ratio as primary outcome. For the current model, we considered a multinomial outcome (CR, PR and NR) rather than a binomial outcome. Therefore, the logistic framework of the NMA was extended to an ordered logistic network meta-analyses (OLNMA) 27 , which means that two logistic models were combined: one for OR versus NR and one for CR versus PR (the latter representing the contribution of CR to OR). The OLNMA were programmed in WinBUGS. Based on heterogeneity tests (i.e. Q-statistic), fixed or random effects OLNMA were applied. 28, 29 The OLNMA specifications are presented in the appendix.
Transition probabilities
Besides the probability of response, the model includes response and line specific transition probabilities to switch to the next line of treatment, which are based on the TTNT data derived from the SLR. It also includes response and line specific transition probabilities of dying, which are based on the OS data from the SLR.
These transition probabilities were defined to be response and line specific but not treatment specific. Therefore, it was assumed that two patients who were treated with different first line treatments, but who had the same level of response (e.g. complete response), had the same probability to switch and to die in the first line.
From the SLR, studies presenting response and line specific OS and TTNT Kaplan-Meier curves were identified and selected to derive the probability of treatment switch and mortality. For first line the following parametric survival curves were fitted over the OS and TTNT Kaplan Meier curves: exponential, Weibull, log-logistic and lognormal. The parametric survival curve with the best fit according to the Akaike and the Schwarz information criteria was chosen. For the second, third and further lines the reported median TTNT and OS durations were converted to monthly transition probabilities using the exponential survival curve. Hereby, within a line of treatment assuming constant treatment switch and mortality transition probabilities over time in second and third line. 30 Implementing time varying transition probabilities in second and third line would have blown up the number of health states and a micro-simulation modelling approach would likely have been required. That was out of scope as it was expected that the added value of such time dependent transition probabilities in second, third and later lines would provide little benefit to the accuracy of the model results
Chapter 5
(e.g. median OS) because the model does consider line specific transition probabilities. By doing so, time is implicitly included by defining line specific transition probabilities.
Sequences
The main aim of the study was to compare ten to twenty sequences that are relevant to clinical practice in terms of OS. It was decided to base the model on the strongest level of evidence. Hence, only treatments for which RCT data were available were included in the sequencing framework. Also, when defining the sequences, only re-treatment of patients with V was allowed, as V was the only treatment for which data on efficacy of retreatment were available. [31] [32] [33] The primary outcome on which the tested sequences were compared was median OS. Secondary outcomes of the model were life expectancy (i.e. mean OS) and time on first, second, third and later lines of treatment.
Sensitivity analyses
A probabilistic sensitivity analysis was conducted to estimate the uncertainty over the predicted median OS estimates per sequence. 34 The extent of uncertainty for the treatment and line specific response rates was derived from the OLNMA. For the line and response specific treatment switch transition probabilities and the transition probabilities to die, the uncertainty was derived from the corresponding literature. 11, 35 The impact of using TTNT rather than TTP was tested in a scenario analysis where it was assumed that patients on continuous treatments (T, R) switch treatment immediately after progression.
Validation of the model
To test the internal validity of the analysis, model predictions in terms of pooled response rates (CR and PR) were compared with reported responses.
For further external validation, the predicted median OS were compared with the reported median OS values of the first line trials that were included in the OLNMA.
The treatment switch and mortality transition probabilities applied in the model were not treatment specific and therefore not derived from the individual trials included in the OLMA. Because the model used response and line specific treatment switch and mortality, comparing predicted and reported OS was considered a valid way of assessing external validity.
Results
Systematic literature review (SLR)
The SLR identified 21 RCTs (17 for newly diagnosed patients, 4 for relapsed/refractory patients) describing nine treatments in front-line (5,038 patients) and five in the relapsed/ refractory setting (1,373 patients). Figure 2 presents the corresponding evidence networks for first and later lines. For first-line ( Figure 2A ) six trials on MPT [14] [15] [16] [17] [18] [19] , three on MPV [20] [21] [22] , three on TD [36] [37] [38] , one on MPVT 22 , one on VPT 21 , one on MPR 23 and MP vs. D 39 were identified. One first-line RCT by Morabito et al. 40 was excluded due to a specific focus on patients with renal impairment. For relapsed patients ( Figure 2B ) three RCTs were identified, two on RD 41, 42 and one for V 43 , both treatments were compared to D. One RCT in the relapsed/refractory setting comparing VD with TD by Hjorth et al. 44 was excluded due to a missing connection to the most extensive network possible for the OLNMA. 
Data synthesis: estimating inputs of the model
OLNMA on Response
Statistical testing using the Q-statistic showed that the homogeneity assumption was violated in first line. Therefore, for the first line of the model, a random effects model for the OLNMA was applied. 28, 29 The actual underlying data and the results of the OLNMA for CR and PR per treatment combination and line of treatment are presented in Figure 3 . NR is not presented as this equals one minus the CR and PR probabilities.
The response rates predicted by the OLNMA are presented in Figure 3 in bold and indicated with a diamond marker. For first line the OLNMA predicted the following CR and PR The model distinguished first, second, third and later lines. Due to a lack of RCTs specifically conducted for second-line treatment, subgroup analyses were used to estimate the responses in second line. [41] [42] [43] For more information please refer to the appendix.
Transition probabilities
For first line the treatment switch and mortality transition probabilities and corresponding uncertainties were derived from Harousseau et al. 11 by means of a Weibull survival model ( Table 1 ). The Weibull curve had the lowest AIC. Harousseau et al was chosen as it provided the most detailed information on response specific OS and TTNT in first line and it has a substantial follow-up.
For second, third and further lines transition probabilities, time independent transition probabilities were applied (Table 1) . For second and third line these transition probabilities were derived from the published TTNT and OS Kaplan Meier curves from the APEX trial. OS transition probabilities for later lines were based on a publication on the SUMMIT trial by Richardson et al. 43 This trial included patients who had already been treated with numerous treatments before entering the trial. Please note that for consistency the treatment switch and mortality transition probabilities for all treatment (combinations) were derived from V trials.
Sequencing model
The Markov model combined the line and treatment specific responses from the OLNMA (Figure 2) , with the line and response specific treatment switch and mortality transition probabilities (Table 1) . Within the Markov model seventeen sequences were constructed based on commonly used front-line regimens MP, MPT, MPR+R, MPV and MPVT. For all initial treatments in combination with MP except for MPR (i.e. MP, MPT, MPV and MPVT) four sequences were investigated. For MPR one sequence was investigated because retreatment with RD was not allowed in our model and D monotherapy in second line is not considered a commonly used second line treatment option. Note that no RCTs have been conducted for T in the relapsed setting ( Figure 2 ). Therefore T in the relapsed setting could not be included in the sequences.
The median OS per sequence and its corresponding uncertainty are presented in Figure 4 together with the estimated mean survival durations within first, second, third and later lines of treatment. For instance, the model predicted that patients treated with MPVT,V,RD in 1 st , 2 nd and 3 rd line respectively, had 48 [95%CI 40-59] month median survival and 54.6 months mean survival. Moreover, it was expected that on average these patients would remain in 1 st , 2 nd , 3 rd and later lines for 26.6, 9.9, 7.6 and 10.6 months, respectively. Moreover, the sequence had a 20.5% probability of being the most effective sequence of those tested. The survival analysis showed that the median OS for the sequences starting with MP, MPT, MPV and MPVT vary between 40-43, 42-45, 44-47 and 46-49 months respectively. The median survival for a sequence starting with MPR, for which only one sequence was tested, was estimated at 43 months.
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Sensitivity analyses
The difference between TTP and TTNT is less apparent in first line than in later lines. Therefore, the scenario analyses in which patients on continuous treatments (T, R) switch immediately after progression reduced the corresponding OS estimates by less than 5%.
Model validation
In terms of internal validity, at face value the pooled response rates seem to correspond with the underlying data ( Figure 3 ).
With respect to external validity, the modelled median survival data ( Figure 4 ) corresponds well with the reported median survival estimates for patients with MM reported in single arm studies or combinations that were not included in the present analyses. 7, 8, [45] [46] [47] [48] These studies report estimates of 24 to >48 months. Please note that the reported data on median OS (Table 2) is quite heterogeneous. For instance, the range of reported OS for MP and MPT is quite large, which can partly be explained by differences in dosing and differences in subsequent lines of treatment. Also, not all trials allow for a direct extrapolation of the reported benefit in terms of response to OS. 15, 23 Table 2 : Overview of published first line trials in terms of treatments and dosages applied and the corresponding results in terms of response, and median OS. In Table 3 and Table 4 the details on the extracted data from the SLR are presented.
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OLNMA model
Values for categories used in the OLNMA: The following logistic link function was applied separately for 1st, 2nd and 3rd line trials:
Where trial specific (i) base line treatment OR probability treatment effect (log odds) vs reference treatment (t), which is MP in 1st line and D in relapsed patient. For the reference treatments is zero.
trial specific (i) base line treatment CR probability within OR treatment effect (log odds) vs reference treatment (t), which is MP in 1st line and D in relapsed patient. For the reference treatments is zero.
Estimating pooled CR, PR, NR rates per treatment and line of treatment
The pooled estimates for the probabilities of CR, PR and NR per treatment were estimated by combining the pooled α's with the pooled δ's. The α's were pooled over the reference treatments (MP arms in 1st line and Dex arms in 2nd and 3rd line). The α's of the MPV trial was used as anchor point in first line. The δ's from the random effects were also pooled. By adding the pooled treatment specific deltas to the pooled α's, the corresponding CR, PR and NR probabilities for the treatments were estimated.
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Estimation second line response (CR, PR, NR probabilities)
Due to a lack of specific second line RCTs, the responses for second line treatments were estimated based on the third line (relapsed) OLNMA responses combined with subgroup analyses reported specifically on the treatment effect of second line patients vs. later line patients. [41] [42] [43] Unfortunately, only overall response was reported in these second line subgroup analyses and not specific CR and PR rates. Hence, it was assumed that the weight of CR and PR in OR (second of the two order logistic regressions) was the same in second and third line. This way we could estimate CR, PR and NR for second line RD, V and D as well. Table 5 presents the baseline risk for overall response (OR) and complete response proportion of OR observed in the 15 trials individually. Trial 6 was used as baseline risk for overall response, α OR , and baseline risk for complete response proportion of OR, α CR . When combining results from Table 5 and Table 6 the proportions of CR, PR and NR can be calculated as outlined in Table 7 for MPV. Figure 4 : Overview of median overall survival (OS) estimates with their corresponding 95% credible intervals (CrI) and mean OS and duration per line of treatment for the selected sequences. Table 3 : Data extraction from studies obtained from the systematic literature review: first-line regimens. Each cell gives the numbers of patients who achieved CR and NR, and the denominator are the number of patients enrolled in the study, i.e. "CR, NR; N". Table 4 : Data extraction from studies obtained from the systematic literature review: relapsed/refractory regimens.
OLNMA coefficients and calculation example for MP and MPV in first line
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1 Chapter 5 Chapter 5 49 . This might be surprising as the model input for first line was largely derived from VISTA. The main reason for this underestimation of the model is the use of APEX data to estimate OS and TTNT transition probabilities for second and third line. Patients going to second line after VISTA were patients 50 who on average received better treatment compared to APEX patients, given that the VISTA trial is more recent than the APEX trial. Hence, the second and third line TTNT and OS transition probabilities derived from APEX are likely to be higher than for patients after VISTA. This causes an underestimation of the modelled median OS.
Although an NMA is currently the best way to indirectly compare and pool data from multiple trials 51, 52 , there are some limitations. The main end-point in an NMA is the relative treatment effect in terms of the log odds ratio. 51, 52 Due to this relative treatment effect and the usually low CR but varying rates in the control arms of trials in MM, the pooled CR rates for active treatments were quite sensitive to this approach. For instance, for relapsed patients the CR rate for D in the APEX trial was 1% and in the two RD trials it was between 1% and 3%, which in the end is a three-fold increase. As a consequence, the OLNMA predicted that the CR of V in relapsed patients is higher (11.7%) than reported in the clinical trial (9%). The opposite is true for RD where the OLMNA predicted a CR of 11.1%, whereas the trials showed a CR of 14-16%. Conversely, in first line the OLNMA predicted half of the observed CR for RD. This is explained by the evidence path that the OLNMA is using to predict RD through D to MP and the relationship of D versus MP as 2% versus 4%, resulting in halving the RD estimate in the OLNMA. Also, the OLNMA could only include treatments that have been investigated in RCTs, whereas important treatment combinations (e.g. TD 53 and VD 54 ) in daily practice are based on evidence from single arm studies. This limited the number of relevant sequences that could be tested in the model.
Response was the key driver of this model. Haematologists might criticize our categorization of response, as newer trials often report more response categories. We also investigated if a differentiation with just OR and NR, as well as a differentiation between CR, nCR, VGPR, PR,
and NR, would work. However, the first one seemed too rough and the latter suffered from a lack of trials reporting on nCR and VGPR. Therefore, for this first modelling attempt, we chose to continue with the initial approach. More refined categories could be included in a future update of the model when results of newer RCTs using the more refined response categories are published.
This first sequencing model is on purpose purely based on the strongest level of evidence (randomized controlled trial) data. Sequencing is, however, a clinical practice issue that clinicians face and should therefore ideally be modelled by using effectiveness data from real world studies. Clinical practice differs from clinical trials in that doctors might use different dosages, dosing intervals and combinations of treatment than tested in clinical trials. Moreover, patients when considering oral treatments and clinicians when considering IV treatments might be less compliant in real world compared to a clinical trial setting. For instance, in clinical practice T is a real treatment option for relapsed patients. This could not be included in this model, as no RCT for T in relapsed patients exists. However, several observational thalidomide studies in relapsed patients are available. Therefore, for future refinement of this modelling approach, there is a need to pool results from RCTs with real world studies. This is methodologically challenging, so assumptions will be required. Another consideration for future refinement is that the current model assumes the same duration of response over treatments. There is literature available suggesting that the duration of response is likely to be treatment specific. 50 Cross resistance would need to be taken into account. Furthermore, given the available RCT data, we had to assume that response to a specific treatment is independent of response to previous treatments, which might not be fully reflecting clinical reality. Such information can be derived from observational studies. In the current OLNMA, we did apply a random effects model to correct for heterogeneity. Future updates should include correction for heterogeneity observed in other variables as well. The model could be extended to patients eligible for SCT. Finally, a model like this could be a proper basis for health economic & policy evaluations, by including both costs and effects of treatments.
In health economics most oncology models are Markov models with the following health states: progression-free survival, survival in progression and death; or they may even be limited to the health states alive and death. [55] [56] [57] These kinds of models address the question of whether treatment A is more cost-effective than treatment B. They don't capture the fact that in clinical practice patients are treated with different lines of treatment which could affect the most important outcome OS. The current approach does.
Treatment sequencing is a relevant question in daily clinical practice and for guideline development in MM. In a broader perspective assessing treatment sequences may be important in other cancers and other chronic diseases such as rheumatoid arthritis and schizophrenia. The main challenges are data requirements, heterogeneity of data and lack of RCTs to fill the model with all treatment combinations over all lines of therapy that are applied in clinical practice. Despite the challenges, we showed that it is possible to create a first framework of the model that demonstrates differences in the benefits of treatment sequences. In general, face validity was good. This work should be viewed as a first attempt that requires refinement once new data will become available, as the MM treatment landscape will continue to evolve. The approach is promising though, as it would allow for an early evaluation of the benefit of current and new treatment options at a certain place in the treatment.
